Curated News
By: NewsRamp Editorial Staff
September 08, 2026
Quantum BioPharma's Lucid-MS Gets FDA Nod for Phase 2 MS Trial
TLDR
- Quantum BioPharma gains edge with FDA clearance for Lucid-MS phase 2 trial and Buy rating from Rodman & Renshaw.
- Lucid-MS inhibits PAD2 to stop demyelination, showing favorable safety in phase 1, now moving to phase 2 trials.
- Lucid-MS aims to treat multiple sclerosis by targeting demyelination, potentially improving patients' quality of life.
- Quantum BioPharma collaborates with Harvard to develop a PET tracer that visualizes demyelination in real time.
Impact - Why it Matters
This news matters because it signals a potential breakthrough in multiple sclerosis treatment. Lucid-MS targets the root cause of disability—demyelination—rather than just managing symptoms, offering hope for disease modification and possibly reversal. For the millions living with MS, this could mean improved quality of life and new treatment options. For investors, it represents a pivotal clinical milestone that could drive significant value for Quantum BioPharma, especially given the analyst endorsement. The broader implication is a shift toward regenerative and targeted therapies in neurology, which could transform how we approach neurodegenerative diseases.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of Lucid-MS, a first-in-class drug candidate for multiple sclerosis (MS). The trial will be a randomized, double-blind, placebo-controlled study, marking a significant milestone as Lucid-MS moves from preclinical success to human testing in MS patients. Unlike existing treatments that broadly suppress the immune system, Lucid-MS inhibits peptidyl arginine deiminase 2 (PAD2) to target demyelination, the underlying cause of MS disability. The FDA's green light follows favorable Phase 1 results in healthy volunteers, where Lucid-MS demonstrated a promising safety and tolerability profile. This development positions Quantum BioPharma at the forefront of a potential paradigm shift in MS therapy, focusing on myelin repair rather than mere symptom management.
Quantum BioPharma is simultaneously advancing a parallel research collaboration with scientists at Massachusetts General Hospital and Harvard Medical School to develop a PET imaging tracer that could quantify demyelination in real-time, potentially enabling earlier diagnosis and treatment monitoring. The company is also drawing attention from financial analysts, with Rodman & Renshaw initiating coverage with a Buy rating and an $8 price target. This coverage places Quantum BioPharma alongside major biopharmaceutical players like Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN), all of whom are exploring innovative approaches to neurological diseases.
Beyond MS, Quantum BioPharma has a diversified pipeline, including UNBUZZD, a product for alcohol misuse, and retains royalties from its OTC spin-off. The company's commitment to tackling challenging neurodegenerative and metabolic disorders underscores its potential to impact millions of patients worldwide. As Quantum BioPharma prepares to enroll patients in the Phase 2 trial, the medical community and investors alike will be watching closely for data that could redefine MS treatment paradigms.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Gets FDA Nod for Phase 2 MS Trial
